Lunai Bioworks Statistics Share Statistics Lunai Bioworks has 172.12M
shares outstanding. The number of shares has increased by 46.03%
in one year.
Shares Outstanding 172.12M Shares Change (YoY) 46.03% Shares Change (QoQ) 34.66% Owned by Institutions (%) 14.13% Shares Floating 9.63M Failed to Deliver (FTD) Shares 7,596 FTD / Avg. Volume 0.32%
Short Selling Information The latest short interest is 5.05M, so 2.94% of the outstanding
shares have been sold short.
Short Interest 5.05M Short % of Shares Out 2.94% Short % of Float 4.08% Short Ratio (days to cover) 2.51
Valuation Ratios The PE ratio is -1.86 and the forward
PE ratio is null.
Lunai Bioworks's PEG ratio is
-0.1.
PE Ratio -1.86 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 1.14 P/FCF Ratio -13.6 PEG Ratio -0.1
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Lunai Bioworks.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.07,
with a Debt / Equity ratio of 0.03.
Current Ratio 0.07 Quick Ratio 0.07 Debt / Equity 0.03 Debt / EBITDA -0.05 Debt / FCF -0.34 Interest Coverage -80.73
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-3.23M Employee Count 25 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -92.19% in the
last 52 weeks. The beta is 0.53, so Lunai Bioworks's
price volatility has been higher than the market average.
Beta 0.53 52-Week Price Change -92.19% 50-Day Moving Average 2.25 200-Day Moving Average 5.21 Relative Strength Index (RSI) 34.8 Average Volume (20 Days) 2,364,422
Income Statement
Revenue n/a Gross Profit -121.86K Operating Income -81.64M Net Income -80.65M EBITDA -81.52M EBIT -79.64M Earnings Per Share (EPS) -0.84
Full Income Statement Balance Sheet The company has 220.47K in cash and 3.79M in
debt, giving a net cash position of -3.57M.
Cash & Cash Equivalents 220.47K Total Debt 3.79M Net Cash -3.57M Retained Earnings -332.46M Total Assets 117.73M Working Capital -25.17M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -10.97M
and capital expenditures -70.43K, giving a free cash flow of -11.04M.
Operating Cash Flow -10.97M Capital Expenditures -70.43K Free Cash Flow -11.04M FCF Per Share -0.11
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields RENB does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for RENB.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 30, 2025. It was a
backward
split with a ratio of 1:10.
Last Split Date Sep 30, 2025 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -6.72 Piotroski F-Score 5
